Opinion|Videos|July 16, 2024
Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis
Medical experts discuss the failure of evobrutinib to meet its primary endpoint in phase 3 trials, review the primary outcomes of the phase 2B study of tolebrutinib in relapsing multiple sclerosis, examine payers' perspectives on the currently available data for tolebrutinib, and briefly describe the design of the HERCULES trial.
Advertisement
Video content above is prompted by the following questions:
- Evobrutinib did not meet its primary endpoint in phase 3 trials. Were you surprised by these results?
- What were the primary outcomes of the phase 2B study of tolebrutinib in relapsing multiple sclerosis?
- What was seen in the 3-year data?
- How do payers view the currently available data of tolebrutinib?
- Tolebrutinib is also under investigation in non-relapsing secondary progressive multiple sclerosis. Why is there a need to investigate therapies in this phenotype and what is the phase 3 HERCULES trial design?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- MS Biomarkers Could Lead to a New Era of Personalized Care
September 10th 2025
- Future Therapies Targeting Epstein-Barr Virus Could Help Combat MS
September 5th 2025
- Industry Payments Linked to Prescribing Patterns in MS Care
August 28th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
2
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5